Article
Immunology
Helal F. Hetta, Alaa A. A. Mohamed, Asmaa M. Zahran, Safaa A. Mahran, Marwa M. Y. Sayed, Mohamed G. A. Saleh, Khaled Abdelazeem, Gaber El-Saber Batiha, Salim Al-Rejaie, Yasir Waheed, Khalid Muhammad, Manal M. Hassanien
Summary: The study found a significant decrease in B cell and regulatory cell numbers in Behcet Disease patients. Regulatory B cells showed an upregulation in patients with genital ulcers or vascular disease. Total B lymphocytes and Bregs were associated with disease activity and ESR, but not with CRP, sexual function, or depression scores. Low-dose aspirin was linked to higher proportions of Bregs.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Engineering, Environmental
Chenglong Wang, Xiaolin Xu, Shuhan Xiong, Peipei Zhang, Jia Yuan, Xuzhu Gao, Wencai Guan, Fanchen Wang, Xin Li, Tao Leng, Hongjing Dou, Guoxiong Xu
Summary: Chemoresistance is a major cause of chemotherapy failure and patient death. However, current approaches to reversing chemoresistance are limited. This study developed calcium-chelated nanoparticles that can replenish calcium ions in chemoresistant cancer cells. These nanoparticles released calcium ions more rapidly in the acidic tumor microenvironment, restoring calcium homeostasis and reversing chemoresistance in various cancer cells. Mechanistically, the nanoparticles affected the expression of chemoresistant genes and promoted cancer cell apoptosis through inhibiting the NF-kappa B signaling pathway. These findings provide insight into an effective approach for reversing chemoresistance, suggesting the potential applications of calcium-chelated nanoparticles in treating chemoresistant patients.
CHEMICAL ENGINEERING JOURNAL
(2022)
Article
Oncology
Meghan E. Sise, Qiyu Wang, Harish Seethapathy, Daiana Moreno, Destiny Harden, R. Neal Smith, Ivy A. Rosales, Robert B. Colvin, Sarah Chute, Lynn D. Cornell, Sandra M. Herrmann, Riley Fadden, Ryan J. Sullivan, Nancy J. Yang, Sara Barmettler, Sophia Wells, Shruti Gupta, Alexandra-Chloe Villani, Kerry L. Reynolds, Jocelyn Farmer
Summary: Non-invasive biomarkers such as elevated sIL-2R level and flow cytometric markers of B and T cell dysregulation may aid in the diagnosis of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis).
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Richard A. Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B. Jones, Thomas Marron, Jaime R. Merchan, Brett G. M. Hughes, Stephen B. Willingham
Summary: This study evaluated the effects of Mupadolimab on immune cells and found that it activates B cells and stimulates the production of antigen specific antibodies. These results support further investigation of Mupadolimab as an immunotherapy for cancer and its potential use as a vaccine adjuvant.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Rheumatology
Filipe Barcelos, Catarina Martins, Nathalie Madeira, Miguel Angelo-Dias, Joana Cardigos, Nuno Alves, Jose Vaz-Patto, Jaime Cunha-Branco, Luis-Miguel Borrego
Summary: In Sjogren's syndrome, a distinctive lymphocyte subset distribution profile seems to be associated with positive anti-SSA antibody. Specifically, SSA+SjS patients show increased percentages of IL-21(+)CD4(+) and CD8(+) T cells, suggesting their potential involvement in disease pathogenesis and activity, and their utility for prognosis and assessment of response to therapy.
CLINICAL RHEUMATOLOGY
(2021)
Article
Oncology
Shanying Gui, W. Quinn O'Neill, Theodoros N. Teknos, Quintin Pan
Summary: This study found that IGJ is a robust and independent prognostic biomarker for disease-specific mortality in HPV+ HNSCC. Patients with low IGJ have a significantly increased risk of disease-specific death and can effectively identify early disease-specific mortality.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Microbiology
Jacob T. Bailey, Safiehkhatoon Moshkani, Catherine Rexhouse, Jesse L. Cimino, Michael D. Robek
Summary: Hepatitis B virus (HBV) is a leading cause of viral hepatitis with a significant impact on global mortality. Although there is currently no highly effective cure for chronic HBV infection, immunotherapy has emerged as a potential treatment option due to its association with HBV-specific immune responses. However, the lack of suitable animal models for studying HBV has posed challenges in understanding the natural immune response to the virus. This study used a mouse model of HBV replication and demonstrated the crucial role of CD4(+) T cells in the antibody-mediated clearance of HBsAg, as well as their ability to reverse HBsAg persistence.
MICROBIOLOGY SPECTRUM
(2023)
Review
Immunology
Rongzeng Liu, Shushu Du, Lili Zhao, Sahil Jain, Kritika Sahay, Albert Rizvanov, Vera Lezhnyova, Timur Khaibullin, Ekaterina Martynova, Svetlana Khaiboullina, Manoj Baranwal
Summary: Multiple sclerosis is a chronic inflammatory disease of the central nervous system characterized by destruction of the myelin sheath. Immune mechanisms, particularly abnormal lymphocyte activity, play a key role in the pathogenesis of multiple sclerosis. This review summarizes the abnormal function and count of lymphocytes and their contributions to the mechanisms of multiple sclerosis. Additionally, novel therapies aimed at correcting the aberrant function or count of these lymphocytes are discussed.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Dong Li, Lincai Li, Huan Yao, Qian Su, Junsong Ye
Summary: Tl exposure can lead to weight loss and appetite suppression, inhibit B cell development and migration in the bone marrow, and affect the migration of naive CD4+ T cells and recent thymic emigrants.
Article
Endocrinology & Metabolism
Irene Campi, Guia Vannucchi, Ilaria Muller, Elisa Lazzaroni, Nicola Curro, Martina Dainese, Benedetta Montacchini, Danila Covelli, Claudio Guastella, Lorenzo Pignataro, Laura Fugazzola, Maura Arosio, Mario Salvi
Summary: This study compared the efficacy and safety of different doses of RTX in the treatment of active moderate-to-severe GO, suggesting that a single 500 mg dose regimen may be the optimal choice for most patients, as it can effectively improve the condition and enhance quality of life.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Urology & Nephrology
Noemi E. Ginthoer, Katharina Artinger, Marion J. Pollheimer, Martin H. Stradner, Kathrin Eller
Summary: This case demonstrates that obinutuzumab can be successfully used in the treatment of membranous nephropathy associated with IgG4-related disease.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Endocrinology & Metabolism
Laura Claire Lane, Timothy David Cheetham, Salman Razvi, Kathleen Allinson, Simon Henry Schofield Pearce
Summary: The level of KRECs in circulating blood is significantly higher in GD patients compared to healthy controls, and it is positively correlated with thyroid hormones and autoantibodies. Higher KRECs levels in GD patients 6-10 weeks after withdrawal of ATD are associated with a higher risk of hyperthyroidism relapse at 1 year. These findings suggest that KRECs may serve as a marker of disease activity and outcome in GD.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Oncology
Nobuhiko Imahashi, Rafet Basar, Yuefan Huang, Fang Wang, Natalia Baran, Pinaki Prosad Banerjee, Junjun Lu, Ana Karen Nunez Cortes, Nadima Uprety, Emily Ensley, Luis Muniz-Feliciano, Tamara J. Laskowski, Judy S. Moyes, May Daher, Mayela Mendt, Lucila N. Kerbauy, Mayra Shanley, Li Li, Francesca Lorraine Wei Inng Lim, Hila Shaim, Ye Li, Marina Konopleva, Michael Green, Jennifer Wargo, Elizabeth J. Shpall, Ken Chen, Katayoun Rezvani
Summary: This study shows that activated B cells suppress T-cell responses through metabolic competition, including increased oxygen consumption and glucose deprivation. These findings provide new insights into immunometabolism and its potential implications for cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Minyu Wang, Soroor Zadeh, Angela Pizzolla, Kevin Thia, David E. Gyorki, Grant A. McArthur, Richard A. Scolyer, Georgina Long, James S. Wilmott, Miles C. Andrews, George Au-Yeung, Ali Weppler, Shahneen Sandhu, Joseph A. Trapani, Melissa J. Davis, Paul Joseph Neeson
Summary: This study found that treatment-naive BRAF-mutant melanoma has a distinct immune composition compared to BRAF wild-type melanoma, with significantly decreased CD8(+) T cells and increased B cells and CD4(+) T cells in the tumor microenvironment. Further mechanistic studies are needed to understand how this difference in immune composition affects the response to immune checkpoint blockade therapy in BRAF-mutant melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Aubrey S. Smith, Hannah M. Knochelmann, Megan M. Wyatt, Guillermo O. Rangel Rivera, Amalia M. Rivera-Reyes, Connor J. Dwyer, Michael B. Ware, Anna C. Cole, David M. Neskey, Mark P. Rubinstein, Bei Liu, Jessica E. Thaxton, Eric Bartee, Chrystal M. Paulos
Summary: TLR agonists can be repurposed ex vivo to condition T cells, improving immunotherapy and revealing the vital role of B cells in the generation of potent CD8(+) T cell-based therapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)